Cancer-like epigenetic derangements of human pluripotent stem cells and their impact on applications in regeneration and repair

Current Opinion in Genetics and Development

Volumn 28, Issue , 2014, Pages 43-49

  Huo, Jeffrey S ^a,b   Baylin, Stephen B ^b   Zambidis, Elias T ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE;

ARTICLE; CARCINOGENICITY; CELL CULTURE; CELL DIFFERENTIATION; CELL REGENERATION; CONTROLLED STUDY; DNA METHYLATION; EMBRYONAL CARCINOMA; EMBRYONIC STEM CELL; EPIGENETICS; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; NEOPLASM; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; X CHROMOSOME; ANIMAL; GENETICS; PATHOLOGY; WOUND HEALING;

ANIMALS; CELL DIFFERENTIATION; EPIGENOMICS; HUMANS; NEOPLASMS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; WOUND HEALING;

EID: 84907958998     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2014.09.008     Document Type: Review

References (55)

1. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
2. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
3. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
4. Osafune K., Caron L., Borowiak M., Martinez R.J., Fitz-Gerald C.S., Sato Y., Cowan C.A., Chien K.R., Melton D.A. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 2008, 26:313-315.
5. Di Giorgio F.P., Boulting G.L., Bobrowicz S., Eggan K.C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008, 3:637-648.
6. Chang K.H., Nelson A.M., Fields P.A., Hesson J.L., Ulyanova T., Cao H., Nakamoto B., Ware C.B., Papayannopoulou T. Diverse hematopoietic potentials of five human embryonic stem cell lines. Exp Cell Res 2008, 314:2930-2940.
7. Hu B.Y., Weick J.P., Yu J., Ma L.X., Zhang X.Q., Thomson J.A., Zhang S.C. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 2010, 107:4335-4340.
8. Boulting G.L., Kiskinis E., Croft G.F., Amoroso M.W., Oakley D.H., Wainger B.J., Williams D.J., Kahler D.J., Yamaki M., Davidow L., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011, 29:279-286.
9. Kajiwara M., Aoi T., Okita K., Takahashi R., Inoue H., Takayama N., Endo H., Eto K., Toguchida J., Uemoto S., et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012, 109:12538-12543.
10. Mills J.A., Wang K., Paluru P., Ying L., Lu L., Galvao A.M., Xu D., Yao Y., Sullivan S.K., Sullivan L.M., et al. Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines. Blood 2013, 122:2047-2051.
11. Nasu A., Ikeya M., Yamamoto T., Watanabe A., Jin Y., Matsumoto Y., Hayakawa K., Amano N., Sato S., Osafune K., et al. Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin. PLOS ONE 2013, 8:e53771.
12. Hynes K., Menicanin D., Mrozik K., Gronthos S., Bartold P.M. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. Stem Cells Dev 2014, 23:1084-1096.
13. Bock C., Kiskinis E., Verstappen G., Gu H., Boulting G., Smith Z.D., Ziller M., Croft G.F., Amoroso M.W., Oakley D.H., et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144:439-452.
14. Guenther M.G., Frampton G.M., Soldner F., Hockemeyer D., Mitalipova M., Jaenisch R., Young R.A. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 2010, 7:249-257.
15. Newman A.M., Cooper J.B. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell 2010, 7:258-262.
16. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., Antosiewicz-Bourget J., O'Malley R., Castanon R., Klugman S., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
17. Nazor K.L., Altun G., Lynch C., Tran H., Harness J.V., Slavin I., Garitaonandia I., Muller F.J., Wang Y.C., Boscolo F.S., et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell Stem Cell 2012, 10:620-634.
18. Ruiz S., Diep D., Gore A., Panopoulos A.D., Montserrat N., Plongthongkum N., Kumar S., Fung H.L., Giorgetti A., Bilic J., et al. Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012, 109:16196-16201.
19. Huang K., Shen Y., Xue Z., Bibikova M., April C., Liu Z., Cheng L., Nagy A., Pellegrini M., Fan J.-B., et al. A panel of CpG methylation sites distinguishes human embryonic stem cells and induced pluripotent stem cells. Stem Cell Reports 2013, 2:36-43.
20. Wang T., Wu H., Li Y., Szulwach K.E., Lin L., Li X., Chen I.P., Goldlust I.S., Chamberlain S.J., Dodd A., et al. Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol 2013, 15:700-711.
21. Kumar R., DiMenna L., Schrode N., Liu T.C., Franck P., Munoz-Descalzo S., Hadjantonakis A.K., Zarrin A.A., Chaudhuri J., Elemento O., et al. AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes. Nature 2013, 500:89-92.
22. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
23. Lee A.S., Tang C., Rao M.S., Weissman I.L., Wu J.C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 2013, 19:998-1004.
24. Yamashita A., Liu S., Woltjen K., Thomas B., Meng G., Hotta A., Takahashi K., Ellis J., Yamanaka S., Rancourt D.E. Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. Sci Rep 2013, 3:1978.
25. Ohm J.E., Mali P., Van Neste L., Berman D.M., Liang L., Pandiyan K., Briggs K.J., Zhang W., Argani P., Simons B., et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res 2010, 70:7662-7673.
26. Ghosh Z., Huang M., Hu S., Wilson K.D., Dey D., Wu J.C. Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res 2011, 71:5030-5039.
27. Koyanagi-Aoi M., Ohnuki M., Takahashi K., Okita K., Noma H., Sawamura Y., Teramoto I., Narita M., Sato Y., Ichisaka T., et al. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proc Natl Acad Sci U S A 2013, 110:20569-20574.
28. Griscelli F., Feraud O., Oudrhiri N., Gobbo E., Casal I., Chomel J.C., Bieche I., Duvillard P., Opolon P., Turhan A.G., et al. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells. Am J Pathol 2012, 180:2084-2096.
29. Ohnishi K., Semi K., Yamamoto T., Shimizu M., Tanaka A., Mitsunaga K., Okita K., Osafune K., Arioka Y., Maeda T., et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014, 156:663-677.
30. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
31. Doi A., Park I.H., Wen B., Murakami P., Aryee M.J., Irizarry R., Herb B., Ladd-Acosta C., Rho J., Loewer S., et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009, 41:1350-1353.
32. Ku M., Koche R.P., Rheinbay E., Mendenhall E.M., Endoh M., Mikkelsen T.S., Presser A., Nusbaum C., Xie X., Chi A.S., et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008, 4:e1000242.
33. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-236.
34. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., et al. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39:157-158.
35. Easwaran H., Johnstone S.E., Van Neste L., Ohm J., Mosbruger T., Wang Q., Aryee M.J., Joyce P., Ahuja N., Weisenberger D., et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012, 22:837-849.
36. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Chen W., Daniel V.C., Yu W., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007, 39:237-242.
37. Chen J., Liu H., Liu J., Qi J., Wei B., Yang J., Liang H., Chen Y., Wu Y., Guo L., et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet 2013, 45:34-42.
38. Sridharan R., Gonzales-Cope M., Chronis C., Bonora G., McKee R., Huang C., Patel S., Lopez D., Mishra N., Pellegrini M., et al. Proteomic and genomic approaches reveal critical functions of H3K9 methylation and heterochromatin protein-1 gamma in reprogramming to pluripotency. Nat Cell Biol 2013, 15:872-882.
39. Geutjes E.J., Bajpe P.K., Bernards R. Targeting the epigenome for treatment of cancer. Oncogene 2012, 31:3827-3844.
40. Barakat T.S., Gribnau J. X chromosome inactivation in the cycle of life. Development 2012, 139:2085-2090.
41. Tesar P.J., Chenoweth J.G., Brook F.A., Davies T.J., Evans E.P., Mack D.L., Gardner R.L., McKay R.D. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007, 448:196-199.
42. Bruck T., Benvenisty N. Meta-analysis of the heterogeneity of X chromosome inactivation in human pluripotent stem cells. Stem Cell Res 2011, 6:187-193.
43. Anguera M.C., Sadreyev R., Zhang Z., Szanto A., Payer B., Sheridan S.D., Kwok S., Haggarty S.J., Sur M., Alvarez J., et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell 2012, 11:75-90.
44. Lessing D., Anguera M.C., Lee J.T. X chromosome inactivation and epigenetic responses to cellular reprogramming. Annu Rev Genomics Hum Genet 2013, 14:85-110.
45. Bruck T., Yanuka O., Benvenisty N. Human pluripotent stem cells with distinct X inactivation status show molecular and cellular differences controlled by the X-Linked ELK-1 gene. Cell Rep 2013, 4:262-270.
46. Yildirim E., Kirby J.E., Brown D.E., Mercier F.E., Sadreyev R.I., Scadden D.T., Lee J.T. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 2013, 152:727-742.
47. Park T.S., Huo J.S., Peters A., Talbot C.C., Verma K., Zimmerlin L., Kaplan I.M., Zambidis E.T. Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors. PLoS ONE 2012, 7:e42838.
48. Park T.S., Bhutto I., Zimmerlin L., Huo J.S., Nagaria P., Miller D., Rufaihah A.J., Talbot C., Aguilar J., Grebe R., et al. Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation 2014, 129:359-372.
49. Zhong X., Gutierrez C., Xue T., Hampton C., Vergara M.N., Peters A., Zambidis E.T., Meyer J., Gamm D.M., Gamm K.-W., et al. Human iPSC-derived three-dimensional retinal cups with functional photoreceptors. Nat Commun 2014, 5. Article 4047. 10.1038/ncomms5047.
50. Guo S., Zi X., Schulz V.P., Cheng J., Zhong M., Koochaki S.H., Megyola C.M., Pan X., Heydari K., Weissman S.M., et al. Nonstochastic reprogramming from a privileged somatic cell state. Cell 2014, 156:649-662.
51. De Los Angeles A., Loh Y.-H., Tesar P.J., Daley G.Q. Accessing naïve human pluripotency. Curr Opin Genet Dev 2012, 22:272-282.
52. Tomoda K., Takahashi K., Leung K., Okada A., Narita M., Yamada N.A., Eilertson K.E., Tsang P., Baba S., White M.P., et al. Derivation conditions impact x-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell 2012, 11:91-99.
53. Gafni O., Weinberger L., Mansour A.A., Manor Y.S., Chomsky E., Ben-Yosef D., Kalma Y., Viukov S., Maza I., Zviran A., et al. Derivation of novel human ground state naive pluripotent stem cells. Nature 2013, 504:282-286.
54. Honda A., Hatori M., Hirose M., Honda C., Izu H., Inoue K., Hirasawa R., Matoba S., Togayachi S., Miyoshi H., et al. Naive-like conversion overcomes the limited differentiation capacity of induced pluripotent stem cells. J Biol Chem 2013, 288:26157-26166.
55. Ware C.B., Nelson A.M., Mecham B., Hesson J., Zhou W., Jonlin E.C., Jimenez-Caliani A.J., Deng X., Cavanaugh C., Cook S., et al. Derivation of naive human embryonic stem cells. Proc Natl Acad Sci U S A 2014, 111:4484-4489.